Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6,634 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Risk factors for relapse of immune-related pneumonitis after 6-week oral prednisolone therapy: a follow-up analysis of a phase II study.
Karayama M, Inui N, Inoue Y, Yasui H, Hozumi H, Suzuki Y, Furuhashi K, Fujisawa T, Enomoto N, Asada K, Nishimoto K, Fujii M, Matsui T, Matsuura S, Hashimoto D, Toyoshima M, Ikeda M, Matsuda H, Inami N, Kaida Y, Funayama S, Ichikawa S, Goshima S, Suda T. Karayama M, et al. Among authors: ikeda m. BMC Pulm Med. 2024 Oct 8;24(1):495. doi: 10.1186/s12890-024-03284-3. BMC Pulm Med. 2024. PMID: 39379903 Free PMC article. Clinical Trial.
Systemic Air Embolism and Mediastinal Emphysema after Pneumonia.
Takuma S, Kusagaya H, Nakamura S, Mori R, Oyama Y, Ikeda M, Suda T. Takuma S, et al. Among authors: ikeda m. Am J Respir Crit Care Med. 2021 Jul 1;204(1):95-96. doi: 10.1164/rccm.202002-0266IM. Am J Respir Crit Care Med. 2021. PMID: 33971112 No abstract available.
Chemotherapy for patients with advanced lung cancer with interstitial lung disease: a prospective observational study.
Koda K, Enomoto Y, Aoshima Y, Amano Y, Kato S, Hasegawa H, Matsui T, Yokomura K, Mochizuki E, Matsuura S, Koshimizu N, Morita M, Kojima S, Watanabe A, Oyama Y, Ikeda M, Kusagaya H, Uto T, Sato J, Imokawa S, Kono M, Hashimoto D, Kamiya Y, Toyoshima M, Asada K, Morita M, Mikamo M, Yasui H, Hozumi H, Karayama M, Suzuki Y, Furuhashi K, Fujisawa T, Enomoto N, Nakamura Y, Inui N, Suda T. Koda K, et al. Among authors: ikeda m. Ther Adv Chronic Dis. 2022 Jun 28;13:20406223221108395. doi: 10.1177/20406223221108395. eCollection 2022. Ther Adv Chronic Dis. 2022. PMID: 35782342 Free PMC article.
Serum immune modulators associated with immune-related toxicities and efficacy of atezolizumab in patients with non-small cell lung cancer.
Inoue Y, Inui N, Karayama M, Asada K, Matsuura S, Ikeda M, Uto T, Fujii M, Hashimoto D, Matsui T, Matsuda H, Inami N, Toyoshima M, Kaida Y, Yasui H, Hozumi H, Suzuki Y, Furuhashi K, Enomoto N, Fujisawa T, Suda T. Inoue Y, et al. Among authors: ikeda m. J Cancer Res Clin Oncol. 2023 Jul;149(7):2963-2974. doi: 10.1007/s00432-022-04193-w. Epub 2022 Jul 14. J Cancer Res Clin Oncol. 2023. PMID: 35834011
Cytokine profiling identifies circulating IL-6 and IL-15 as prognostic stratifiers in patients with non-small cell lung cancer receiving anti-PD-1/PD-L1 blockade therapy.
Inoue Y, Inui N, Karayama M, Asada K, Fujii M, Matsuura S, Uto T, Hashimoto D, Matsui T, Ikeda M, Yasui H, Hozumi H, Suzuki Y, Furuhashi K, Enomoto N, Fujisawa T, Suda T. Inoue Y, et al. Among authors: ikeda m. Cancer Immunol Immunother. 2023 Aug;72(8):2717-2728. doi: 10.1007/s00262-023-03453-z. Epub 2023 Apr 26. Cancer Immunol Immunother. 2023. PMID: 37099186 Free PMC article.
Six-week oral prednisolone therapy for immune-related pneumonitis: a single-arm phase II study.
Karayama M, Inui N, Inoue Y, Yasui H, Hozumi H, Suzuki Y, Furuhashi K, Fujisawa T, Enomoto N, Asada K, Uto T, Fujii M, Matsui T, Matsuura S, Hashimoto D, Toyoshima M, Ikeda M, Matsuda H, Inami N, Kaida Y, Funayama S, Ichikawa S, Goshima S, Suda T. Karayama M, et al. Among authors: ikeda m. J Immunother Cancer. 2023 Jul;11(7):e007056. doi: 10.1136/jitc-2023-007056. J Immunother Cancer. 2023. PMID: 37500182 Free PMC article. Clinical Trial.
Olanzapine Plus Triple Antiemetic Therapy for the Prevention of Carboplatin-Induced Nausea and Vomiting: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial.
Inui N, Suzuki T, Tanaka K, Karayama M, Inoue Y, Mori K, Yasui H, Hozumi H, Suzuki Y, Furuhashi K, Fujisawa T, Matsuura S, Nishimoto K, Matsui T, Asada K, Hashimoto D, Fujii M, Niwa M, Uehara M, Matsuda H, Koda K, Ikeda M, Inami N, Tamiya Y, Kato M, Nakano H, Mino Y, Enomoto N, Suda T. Inui N, et al. Among authors: ikeda m. J Clin Oncol. 2024 Aug 10;42(23):2780-2789. doi: 10.1200/JCO.24.00278. Epub 2024 Jun 4. J Clin Oncol. 2024. PMID: 38833659 Free PMC article. Clinical Trial.
6,634 results